A Manifesto for the Future of Law

The Limits of a Verdict

Luigi Mangione will almost certainly be convicted of murder. But the law’s refusal to call his act terrorism reveals a fracture larger than any single verdict. The trial shows us what happens when statutes lag behind reality, when rights collide without resolution, and when corporations stand as symbols but are treated as mere individuals.

Justice was delivered within the narrow confines of the law. But justice, in the eyes of society, feels incomplete.

‍

The Collisions We Can No Longer Ignore

Across this series, five collisions have emerged—each one shaping the architecture of tomorrow’s justice:

1. Terror vs. Rage – The law says killing one CEO is murder, not terrorism. The world sees it differently.

2. Speech vs. Guns – The First and Second Amendments, designed in the 18th century, now collide in the 21st.

3. Lawyers vs. Narratives – Trials are no longer about facts but about the stories lawyers—and soon AI—tell.

4. CEOs vs. Populism – Corporate leaders are no longer managers but symbols, targets of anger in a fragile global economy.

5. Law vs. AI – Our statutes were written for human conspiracies, not machine amplification and digital radicalization.

Each collision reveals the same truth: the law we inherited is not enough for the world we are entering.

‍

AI is the silent accelerant. It can fabricate manifestos, amplify dissent, and distort narratives at a scale no human could match. Courts are unprepared. Governments are slow. Corporations are reactive.

Without global guide rails, AI will not just accelerate crime—it will destabilize trust. Trust in speech, trust in evidence, trust in verdicts. The very fabric of justice will fray.

If nothing changes, the future of rights may unfold like this:

• Free Speech weaponized by algorithms.

• Gun Rights colliding with digital radicalization.

• Privacy Rights eroded by corporate surveillance in the name of security.

• Consumer and Labor Rights shrinking as corporations retreat behind fortress walls.

The more corporations are attacked, the more ordinary people may lose.

‍

Markets will not wait for statutes. When CEOs are killed, investors calculate risk, not morality. If law refuses to classify corporate-directed violence as terror, markets will. The cost will be borne in valuations, capital flows, and public trust.

This is why Mangione’s case matters far beyond Midtown Manhattan. It matters in Shanghai, in Paris, in São Paulo. It matters anywhere CEOs embody systems larger than themselves. If justice is to survive the 21st century, three steps are essential:

1. Redefine Terrorism for the Age of Symbols and AI

Terrorism can no longer be defined only by groups, bombs, and manifestos. It must account for lone actors, symbolic targets, and machine-amplified violence.

2. Reconcile the First and Second Amendments

Rights cannot be treated in isolation. Speech and arms together create outcomes neither amendment envisioned. New frameworks must recognize their collision.

3. Globalize the Architecture of Justice

Violence against corporations is global. AI is global. Markets are global. Law cannot remain parochial. A new architecture of justice must be international, interoperable, and adaptive.

‍

Why These Matter

The Mangione trial is not about one man, one CEO, or one verdict. It is about the cracks in a system we depend on to protect order in an age of chaos.

• If O.J. showed us law cannot contain celebrity and race,

• If Mangione shows us law cannot contain corporate rage and symbolic violence,

• Then the next case will show us law cannot contain AI.

Unless we evolve, justice will lag, markets will decide, and rights will erode.

Because in the end, why these matter is not about Mangione. It is about us—the unfinished architecture of law, the fragile future of rights, and the survival of justice in an age we have only just begun to enter.

‍

The City Must Learn to Live With Water

The modern city has spent more than a century attempting to make water disappear. Rain falls onto roofs, roads and pavements. Gutters collect it. Drains capture it. Pipes bury it. Pumps move it. Rivers are channelled. Wetlands are filled. Coastlines are defended. The engineering objective has largely been straightforward: separate water from urban life as efficiently as possible. That model is reaching its limits. Around 600 million urban residents already live with significant annual flood hazard, according to the World Bank. Globally, 1.81 billion people live in flood-prone areas, while annual urban flood losses could approach $50 billion by 2050. Rapid urbanisation, ageing drainage infrastructure, land subsidence and changing rainfall patterns are interacting with the basic physical reality that cities have covered enormous portions of naturally absorbent ground with concrete and asphalt. Yet the consequential story is not simply that cities need bigger drains. A different philosophy of urban resilience is emerging: parks designed to flood temporarily; streets shaped to carry cloudbursts; wetlands restored as infrastructure; plazas capable of storing stormwater; permeable landscapes that absorb rainfall; buildings elevated or adapted to tolerate inundation; sensors that reveal water movement in real time; and neighbourhoods organised around the understanding that some water cannot — and perhaps should not — be engineered away. The World Bank increasingly describes effective urban flood management as an integration of grey infrastructure, green infrastructure, nature-based systems, planning, warning systems and institutional reform, rather than reliance on any single engineering intervention. The conceptual reversal is enormous. For generations, successful urbanisation meant controlling nature sufficiently to construct the city. The next generation of urbanism may require something more intelligent: designing the city so nature can still function inside it.

The Price of Money Is Becoming Political Again

For much of the post-financial-crisis era, wealthy economies became accustomed to an extraordinary condition: money was cheap. Governments could borrow heavily, companies could finance expansion at modest rates, asset prices could rise on abundant liquidity, and households learned to treat low-cost mortgages as something approaching economic normality. That world is disappearing fast. Across major economies, long-term government borrowing costs have climbed towards levels not seen for years or decades. On 17 August, the US 30-year Treasury yield reached roughly 5.31 per cent, its highest level since 2007. Japan’s 10-year government bond yield subsequently approached 2.95 per cent, a three-decade high, while German borrowing costs have risen to 15-year highs. The OECD describes the present combination of elevated financing requirements and elevated yields as exceptional compared with the previous two decades. Behind those numbers is a larger structural contest. Governments need capital for debt refinancing, defence, infrastructure, pensions, healthcare and climate resilience. Technology companies require extraordinary sums for artificial-intelligence infrastructure. Energy systems require grids, generation and storage. Businesses require investment. Families require mortgages and credit. These demands do not occupy separate universes. They ultimately encounter the same fundamental economic resource: capital. And when many powerful institutions want more of it simultaneously, the price of money stops being an obscure financial-market variable. It becomes a question of who gets financed, at what price, and at whose expense.

Cancer Vaccines Are Becoming Personal

For more than a century, the word vaccine has largely meant prevention: teach the immune system to recognise a threat before disease takes hold. Cancer is forcing medicine to reconsider that architecture. A new generation of experimental therapies is attempting something considerably more individual: sequence a patient’s tumour, identify mutations particular to that cancer, manufacture instructions corresponding to selected tumour-specific targets, and teach the patient’s immune system to recognise what belongs to the cancer growing inside that particular body. On 19 August, Moderna and Merck announced that their Phase III trial of the investigational personalised mRNA therapy intismeran autogene, used with Merck’s checkpoint inhibitor Keytruda after surgery for high-risk melanoma, achieved statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone. The global trial enrolled 1,137 patients with resected stage IIB–IV melanoma. No new safety concerns were identified in the announcement. Full detailed Phase III results remain pending. The result matters because this is not simply another medicine administered to everyone carrying the same diagnosis. Intismeran is designed individually. Tumour and normal tissue are sequenced; mutations are analysed computationally; selected neoantigens — abnormal molecular features produced by the tumour — become the targets encoded into an mRNA therapy manufactured for that patient. Earlier Phase IIb evidence provides important context rather than a substitute for the unreleased Phase III detail. At five-year median follow-up, Moderna and Merck reported that intismeran plus Keytruda reduced the risk of recurrence or death by 49 per cent and distant metastasis or death by 59 per cent compared with Keytruda alone in that smaller study. The larger significance therefore extends beyond melanoma. Medicine has spent generations classifying disease so that patients with sufficiently similar conditions can receive sufficiently similar treatments. Personalised cancer vaccines suggest a different possibility: the diagnosis may identify the disease, while the tumour itself helps design the medicine. If that model succeeds across cancers, one of medicine’s great industrial achievements — standardisation — will begin coexisting with its apparent opposite: manufacturing treatment for one.

A Manifesto for the Future of Law

The Limits of a Verdict

The Collisions We Can No Longer Ignore

Why These Matter

Related Posts

The City Must Learn to Live With Water

The Price of Money Is Becoming Political Again

Cancer Vaccines Are Becoming Personal

Categories

Pages